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ABSTRACT
Background
The distinct clinicoradiological syndrome of reversible basal ganglia lesions associated with extrapyramidal
movement disorders in uremic patients has rarely been described in the literature. There have been no
reported cases from Africa.
Methods
This study is a retrospective analysis of uremic patients presenting with extrapyramidal movement disorders
in Durban, South Africa from 2003 to 2016. A review of all published studies was also undertaken.
Results
Seven patients who presented with this syndrome were identified. An additional 41 cases were reported in
the literature. Our seven cases showed similar characteristics to those previously reported. All patients were
of Asian ethnicity and had dialysis dependent renal failure, 86% (6/7) due to diabetic nephropathy. The most
frequent  presentation  was  parkinsonism  (5/7)  followed  by  chorea  (1/7)  and  dystonia  (1/7).  Typical
neuroimaging findings included bilateral symmetrical basal ganglia abnormalities that were hypodense on
computed tomography scan, and T1 hypointense and T2 hyperintense on magnetic resonance imaging. A
key feature of this syndrome is its reversibility with supportive treatment; Clinical improvement was observed
in 86% (6/7), which was accompanied by radiological regression of lesions in two patients who underwent
follow-up imaging.
Conclusions
The syndrome of acute extrapyramidal movement disorders in uremic patients with bilateral basal ganglia
lesions presents with typical clinical and radiological findings. Awareness of  this syndrome especially in
Asian  diabetic  patients  with  renal  failure  is  important  for  early  recognition  and  appropriate  supportive
management to aid its resolution.
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INTRODUCTION
The  clinicoradiological  findings  of  the  reversible  basal  ganglia  lesions  associated  with  Extrapyramidal
Movement disorders in Uremia Syndrome (from here on referred to as “REMUS”) has been described in the
literature [11, 16, 18]. Characteristic features of this syndrome include the abrupt onset of symptoms, the
presence of bilateral symmetrical basal ganglia lesions on neuroimaging as well as clinical and radiological
reversibility with supportive management.
In a review article in 2008, Li et al. [11] summarised 24 cases of this syndrome published since its first
description in 1998. Thereafter, only case reports and small case series have been documented. The true
incidence in different  populations has not  yet  been established but  the majority of  reports  are  of  Asian
patients. There have been no cases published from Africa [11, 17].
REMUS is distinct from uremic encephalopathy, the more frequent central nervous system complication of
renal  failure.  Uremic  encephalopathy is  characterised  by cortical  involvement  presenting  with  seizures,
impaired level of consciousness, asterixis and myoclonus. Clinically, the syndrome we describe affects the
basal ganglia and therefore manifests with hyperkinetic or hypokinetic movement disorders. Patients may
have disturbances in consciousness, but this is usually mild and not the predominant feature [17].
Considering that knowledge of REMUS is based on limited case reports and one previous review article
published a decade ago [11], an updated description of  the syndrome will  be advantageous to enhance
recognition and optimal management. In this study, we report our experience of patients with REMUS in an
African setting. In addition, we summarised published data of all previously reported cases and compared
these to our series.
METHODS
A retrospective  chart  review was performed on patients  who presented in  renal  failure  with  movement
disorders and bilateral basal ganglia lesions from 2003 through 2016 in Durban, South Africa. The biomedical
research ethics committee (BREC) of University of Kwa Zulu Natal (UKZN) approved the study (BE 038/17).
In addition, we performed a literature search to identify all cases published since the first description of this
syndrome in 1998 until August 2017. Search engines and electronic databases included Pubmed, Google
scholar, Science Direct, Biomed Central and UKZN World Cat. English language articles reporting patients
who met the following clinical criteria were included: uremia (serum urea more than 7.1mmol/l), hypokinetic or
hyperkinetic movement disorders and bilateral basal ganglia lesions on neuroimaging studies. Cases were
excluded if neurological dysfunction was reported in the absence of movement disorders and if other possible
causes of basal ganglia lesions were identified.
Data on the following parameters were extracted for all  cases:  ethnicity, age, gender,  aetiology of  renal
failure,  current  dialysis and duration thereof,  duration of  symptoms,  type of  movement  disorder,  level  of
consciousness,  laboratory  and  imaging  findings,  interventions  provided  and  clinical  and  radiological
outcomes. The country in which the cases were identified was also documented.
STATISTICAL ANALYSIS
Statistical analysis was performed using GraphPad Prism version 6. Continuous and categorical variables are
presented as median and interquartile ranges and, percentages, respectively. Categorical and continuous
variables between groups were compared using Fisher’s exact test and, Mann-Whitney U test, respectively.
A p-value of <0.05 was considered statistically significant.
RESULTS
We included seven cases presenting with REMUS. Details of these seven patients are summarised in Table
1. Amongst them, four (57%) were female. All patients were of Indian ethnicity. The median age was 52 years
(range: 34-65years). Six patients (86%) had diabetic nephropathy as a cause for renal failure and one had
hypertensive nephropathy. All patients were receiving chronic renal replacement therapy; two (29%) received
peritoneal dialysis and five (71%) received haemodialysis for a duration of 18 months (median, range:12-24
months). Patients presented after a median of  21 days (range: 8-75) symptom duration with one patient
reported as having “acute symptom onset” without the number of days of symptoms specified. Five (71%)
patients presented with parkinsonism, one (14%) with chorea and one (14%) with dystonia. Three (43%)
patients had impaired level of consciousness. The median urea was 14 mmol/l (range: 13-18) and creatinine
844 umol/l (range: 754-918, in six patients for whom this result was available). Two (40%) of five patients
were acidotic.
Neuroimaging  performed  included  computed  tomography  (CT)  in  two  patients  (29%)  and  magnetic
resonance imaging (MRI) in six (86%). CT scans showed bilateral basal ganglia hypodensities (Figure 1).
The MRI universally showed bilateral symmetrical basal ganglia signal changes that were hypointense on T1
weighted images hyperintense on T2 weighted images (Figure 2). One patient demonstrated extension of
these abnormalities into the posterior parietal regions and another patient had involvement of the internal and
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external capsules as well as the medial temporal lobes. Of those who had MRI, two showed evidence of
vasogenic and cytotoxic  oedema on diffusion weighted imaging (DWI)  and apparent diffusion coefficient
(ADC)  imaging.  All  patients  were  dialysed.  Medical  therapy included  levodopa in  the  five  patients  with
parkinsonism, haloperidol in the patient with chorea and, a combination of risperidone and clonazepam in the
patient with dystonia. Two patients (29%) showed complete clinical recovery and an additional four (57%)
showed clinical improvement. One patient died shortly after admission due to severe uremia and concurrent
infection. Two patients who underwent follow-up imaging showed radiological improvement.
The literature search identified 38 articles. Seven case reports were excluded due to absence of movement
disorders and three case reports and one case series (2 patients) were excluded due to the possibility of an
alternative/additional etiological cause for basal ganglia lesions (e.g. hypoglycaemia, thiamine deficiency and
drug effects).  From the 27 articles included,  41 cases  were  described.  Details  of  these patients  and a
comparison to our case series are provided in Table 1. No statistically significant results were obtained when
comparing our case series to the previously published cases.
DISCUSSION
REMUS is a rare disorder,  most  commonly reported from Asia. In this first  case series from Africa,  we
describe seven patients with end stage renal failure on chronic renal replacement therapy with this syndrome.
Six  patients  showed  improvement  after  dialysis  and  pharmacotherapy.  Our  patients  showed  similar
characteristics to the 41 cases reported in the literature.
Patient demographics
Including our series, 79% of all cases thus far described in the literature were Asian, as all South African
patients were of Indian ethnicity. Only three Caucasian and three Hispanic cases have been reported from
Europe, America and Australia [2, 3, 6, 8, 11, 19] and there have been no reports of cases with African
ethnicity. This may imply under recognition in these populations or an underlying protective genetic trait.
Renal failure
The most common setting of the syndrome is in patients with diabetic nephropathy and long standing renal
impairment receiving chronic dialysis. Other causes of renal failure that have rarely been associated with
REMUS include Polycystic Kidney Disease and Chronic Glomerulonephritis  [6, 10].  No distinct  additional
precipitants of the syndrome were reported.
Clinical Presentation
This syndrome frequently has an acute or subacute presentation, however longer durations of up to 180 days
have been documented [1]. As reflected in Table 1, parkinsonism is the most common clinical presentation,
followed by chorea,  then dystonia. A single  case reported by Sheu et al.[13],  demonstrated a relapsing
remitting course, with episodes of altered sensorium and dyskinesia followed by parkinsonism, however the
remaining cases, including those in our series, all had a monophasic disease course. We report acidosis in a
smaller proportion of patients than previously described [11] (62% vs 90%).
Neuroimaging findings
A  unique  characteristic  of  REMUS  is  the  uniformity  of  radiological  findings  amongst  various  cases,
particularly the consistent symmetry of basal ganglia abnormalities. Lesions are hypodense on CT scans and
MRI  findings  show  basal  ganglia  T1  weighted  hypointensities  with  corresponding  T2  weighted
hyperintensities. The extent of the signal changes ranges from focal involvement of the putamen or pallidum
to the entire basal ganglia. The abnormalities are most commonly isolated to the basal ganglia, but have also
been reported to extend into the thalamus and adjacent white matter [2,  4,  16].  Gadolinium and iodine
contrast is rarely administered in patients with renal impairment, however in the eight patients who did have
contrasted scans, basal ganglia enhancement was observed in two (25%) [9, 17]. Vasogenic oedema in the
basal ganglia was observed on DWI in 95% (19/20) of cases. However, reduced ADC values suggestive of
cytotoxic oedema were only demonstrated in 63% (12/19) of cases, most commonly affecting the central
portions of the affected basal ganglia regions. Occasionally the presence of petechial haemorrhages within
the basal ganglia lesions have also been reported [13, 17, 20].
Pathogenesis
The precise pathogenesis of the basal ganglia abnormalities in this setting remains unclear, but is likely to be
multifactorial, due to a combination of diabetes, renal failure, toxins and metabolic derangements. Diabetes-
associated microvascular changes in the basal ganglia may render it susceptible to damage. The acute onset
and  spontaneous  improvement  suggests  ischemia  as  a  possible  pathogenic  mechanism  [11,  17,  18].
However, post-mortem analysis performed 10 months after syndrome presentation in a single patient did not
show inflammatory changes  or  blood vessel  damage  in  the  basal  ganglia  [14].  This  may suggest  that
microvascular disease is not a major contributing factor.
Magnetic resonance spectroscopy (MRS) imaging in one case showed findings suggestive of ischemia and
glucose  utilization  failure  [3].  This  was  supported  by F-18  fluorodeoxyglucose  (FDG)  positron  emission
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tomography (PET) scans in two patients performed by Wang et al. [18], which revealed markedly reduced
glucose metabolism in the basal ganglia, especially in the putamen where glucose uptake was almost absent.
The vulnerability of the basal ganglia to numerous toxins and metabolic disturbances is widely accepted [7].
One of  the key features  of  REMUS is  the presence  of  uremia  and therefore  uremic  toxins  have been
implicated in the underlying pathogenesis. At present, no specific toxin has been shown to have a direct
causative  link  but  potential  candidates  include  asymmetric  dimethylarginine  (ADMA),  methylguanidine,
parathyroid hormone and aluminium [11, 17]. Metabolic acidosis may also contribute to the pathogenesis as
similar lesions have been described in patients with normal renal function but with metabolic acidosis due to
other causes, such as methanol intoxication [7, 12].
Combining the above theories, Wang et al. [17] proposed the underlying pathophysiology as follows: Patients
with longstanding diabetes already have sub-optimal basal ganglia function and reserve due to cerebral
micro-angiopathic  changes  and  impaired  energy  utilization.  When  exposed  to  uremic  toxins,  function
decompensates leading to tissue damage and focal oedema manifesting clinically as movement disorders in
the acute phase. As the oedema resolves, clinical and radiological improvement is seen, however cellular
metabolic derangement may persist  which explains why a small  proportion of  patients demonstrate poor
recovery [18].
Management and outcomes
The most significant feature of the syndrome is the spontaneous improvement or even complete resolution,
both  clinically and radiologically,  which  distinguishes  it  from most  of  the  other  causes of  basal  ganglia
abnormalities such as carbon monoxide, hypoxia and other metabolic disorders [11, 15]. Management is
focussed on supportive care particularly intensifying dialysis to treat the acidosis and uremia. In addition,
symptomatic treatment, including levodopa and benserazide for parkinsonism and, dopamine antagonists
and benzodiazepines for hyperkinetic  movement disorders,  have also been administered in 31% (11/36)
cases. However, the contribution of these agents to recovery is uncertain. PET scans using (11 C)-labeled 2-
carbomethoxy-3-(4-fluorophenyl) trophane and (11 C)-labeled raclopride described by Ishii et al. [5], revealed
significant decreases in pre- and postsynaptic dopaminergic neuron function in the basal ganglia bilaterally,
suggesting that levodopa may not be effective in the treatment of parkinsonism in these patients [5]. Overall,
good clinical outcome was seen in 79% of cases whilst radiological resolution or improvement occurred in
94%. This discrepancy may be due to permanent neuronal damage which may go undetected using current
neuroimaging techniques.
CONCLUSION
Although the syndrome of acute extrapyramidal movement disorders in uremic patients with bilateral basal
ganglia lesions is rare, it is important to recognise especially in Asian diabetic patients with renal failure, as
most cases will recover with appropriate supportive measures which includes increased dialysis.
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